Different Interleukin-17-secreting Toll-like Receptor T-cell Subsets Are Associated with Disease Activity in Multiple Sclerosis
Overview
Authors
Affiliations
Signalling through Toll-like receptors (TLRs) may play a role in the pathogenesis of autoimmune diseases, such as multiple sclerosis (MS). In the present study, the expression of TLR-2, -4 and -9 was significantly higher on CD4 and CD8 T-cells from MS patients compared to healthy individuals. Following in-vitro activation, the proportion of interleukin (IL)-17 and IL-6 CD4 and CD8 T-cells was higher in the patients. In addition, the proportion of IFN-γ-secreting TLR CD8 T-cells was increased in MS patients. Among different IL-17 T-cell phenotypes, the proportion of IL-17 TLR CD4 and CD8 T-cells producing IFN-γ or IL-6 were positively associated with the number of active brain lesions and neurological disabilities. Interestingly, activation of purified CD4 and CD8 T-cells with ligands for TLR-2 (Pam3Csk4), TLR-4 [lipopolysaccharide (LPS)] and TLR-9 [oligodeoxynucleotide (ODN)] directly induced cytokine production in MS patients. Among the pathogen-associated molecular patterns (PAMPs), Pam3Csk4 was more potent than other TLR ligands in inducing the production of all proinflammatory cytokines. Furthermore, IL-6, IFN-γ, IL-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) levels produced by Pam3Csk4-activated CD4 cells were directly associated with disease activity. A similar correlation was observed with regard to IL-17 levels released by Pam3Csk4-stimulated CD8 T-cells and clinical parameters. In conclusion, our data suggest that the expansion of different T helper type 17 (Th17) phenotypes expressing TLR-2, -4 and -9 is associated with MS disease activity, and reveals a preferential ability of TLR-2 ligand in directly inducing the production of cytokines related to brains lesions and neurological disabilities.
Shi D, Chen L, Li C, Yang M, Yang W, Cui G Discov Oncol. 2025; 16(1):325.
PMID: 40088359 DOI: 10.1007/s12672-025-02034-z.
Mechanisms governing bystander activation of T cells.
Yosri M, Dokhan M, Aboagye E, Moussawy M, Abdelsamed H Front Immunol. 2024; 15:1465889.
PMID: 39669576 PMC: 11635090. DOI: 10.3389/fimmu.2024.1465889.
Hygino J, Sales M, Sacramento P, Kasahara T, da Silva J, Bilhao R J Inflamm Res. 2024; 17:8775-8797.
PMID: 39564547 PMC: 11573880. DOI: 10.2147/JIR.S476110.
Fornari Laurindo L, Dias J, Cressoni Araujo A, Pomini K, Machado Galhardi C, Rucco Penteado Detregiachi C Front Immunol. 2024; 14:1305933.
PMID: 38259497 PMC: 10800801. DOI: 10.3389/fimmu.2023.1305933.
Analysis of Differential TLR Activation in a Mouse Model of Multiple Sclerosis.
Suvieri C, Volpi C Methods Mol Biol. 2023; 2700:229-247.
PMID: 37603185 DOI: 10.1007/978-1-0716-3366-3_14.